Please use this identifier to cite or link to this item:
|Title:||Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up|
|Authors:||Arévalo, J. F.|
Sanchez, J. G.
Maia, M. [UNIFESP]
Saravia, M. J.
Fernandez, C. F.
Inst Cirugia Ocular
Universidade Federal de São Paulo (UNIFESP)
Hosp Univ Austral
|Publisher:||Nature Publishing Group|
|Citation:||Eye. London: Nature Publishing Group, v. 23, n. 1, p. 117-123, 2009.|
|Abstract:||Aims To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR).Methods Retrospective study of patients with RN due to PDR who were treated with at least one intravitreal injection of 1.25 or 2.5mg of bevacizumab. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits.Results Forty-four eyes of 33 patients with PDR and a mean age of 57.2-years (range: 23 82 years) participated in the study. Thirty-three eyes (75%) had previous panretinal photocoagulation (PRP). Twenty-seven eyes (61.4%) showed total regression of RN on fundus examination with absence of fluorescein leakage, 15 eyes (34.1%) demonstrated partial regression of RN on fundus examination and FA. Follow-up had a mean of 28.4 weeks (range from 24 to 40 weeks). BCVA and OCT demonstrated improvement (P<0.0001). Three eyes without previous PRP ('naive' eyes) and with vitreous haemorrhage have avoided vitreo-retinal surgery. One eye (2.2%) had PDR progression to tractional retinal detachment requiring vitrectomy, and one eye (2.2%) had vitreous haemorrhage with increased intraocular pressure (ghost cell glaucoma). No systemic adverse events were observed.Conclusions Intravitreal bevacizumab resulted in marked regression of RN in patients with PDR and previous PRP, and rapid resolution of vitreous haemorrhage in three naive eyes. Six-months results of intravitreal bevacizumab at doses of 1.25 or 2.5mg in patients with PDR do not reveal any safety concerns.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.